• +1-646-491-9876
    • +91-20-67278686

    Search

    Kidney Cancer-Pipeline Review H2 2017

    Kidney Cancer-Pipeline Review H2 2017

    • Report Code ID: RW00011336546
    • Category Life Sciences
    • No. of Pages 1436
    • Publication Month Dec-17
    • Publisher Name Global Markets Direct
    Kidney Cancer (Renal Cell Cancer)-Pipeline Review, H2 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Kidney Cancer (Renal Cell Cancer)-Pipeline Review, H2 2017, provides an overview of the Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline landscape.

    Kidney cancer also called renal cancer is a disease in which kidney cells become malignant (cancerous) and grows out of control, forming a tumor. Symptoms include blood in urine, loss of appetite, fever that lasts for weeks, extreme fatigue, and anemia, shortness of breath and bone pain. Treatment includes surgery, radiation therapy and chemotherapy.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Kidney Cancer (Renal Cell Cancer)-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Kidney Cancer (Renal Cell Cancer) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Kidney Cancer (Renal Cell Cancer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 1, 15, 94, 88, 5, 78, 12 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 13, 6 and 13 molecules, respectively.

    Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    -The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Cancer (Renal Cell Cancer) (Oncology).
    -The pipeline guide reviews pipeline therapeutics for Kidney Cancer (Renal Cell Cancer) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    -The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    -The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    -The pipeline guide reviews key companies involved in Kidney Cancer (Renal Cell Cancer) (Oncology) therapeutics and enlists all their major and minor projects.
    -The pipeline guide evaluates Kidney Cancer (Renal Cell Cancer) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    -The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    -The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Cancer (Renal Cell Cancer) (Oncology)

    Reasons to buy

    -Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    -Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    -Find and recognize significant and varied types of therapeutics under development for Kidney Cancer (Renal Cell Cancer) (Oncology).
    -Classify potential new clients or partners in the target demographic.
    -Develop tactical initiatives by understanding the focus areas of leading companies.
    -Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    -Formulate corrective measures for pipeline projects by understanding Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline depth and focus of Indication therapeutics.
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    -Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    Table of Contents 2
    Introduction 8
    Kidney Cancer (Renal Cell Cancer)-Overview 9
    Kidney Cancer (Renal Cell Cancer)-Therapeutics Development 10
    Kidney Cancer (Renal Cell Cancer)-Therapeutics Assessment 49
    Kidney Cancer (Renal Cell Cancer)-Companies Involved in Therapeutics Development 73
    Kidney Cancer (Renal Cell Cancer)-Drug Profiles 152
    Kidney Cancer (Renal Cell Cancer)-Dormant Projects 1368
    Kidney Cancer (Renal Cell Cancer)-Discontinued Products 1383
    Kidney Cancer (Renal Cell Cancer)-Product Development Milestones 1387
    Appendix 1402

    List of Tables
    Number of Products under Development for Kidney Cancer (Renal Cell Cancer), H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
    Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
    Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
    Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017
    Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017
    Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017
    Number of Products under Development by Companies, H2 2017 (Contd..7), H2 2017
    Number of Products under Development by Companies, H2 2017 (Contd..8), H2 2017
    Number of Products under Development by Companies, H2 2017 (Contd..9), H2 2017
    Number of Products under Development by Companies, H2 2017 (Contd..10), H2 2017
    Number of Products under Development by Universities/Institutes, H2 2017
    Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
    Products under Development by Companies, H2 2017
    Products under Development by Companies, H2 2017 (Contd..1), H2 2017
    Products under Development by Companies, H2 2017 (Contd..2), H2 2017
    Products under Development by Companies, H2 2017 (Contd..3), H2 2017
    Products under Development by Companies, H2 2017 (Contd..4), H2 2017
    Products under Development by Companies, H2 2017 (Contd..5), H2 2017
    Products under Development by Companies, H2 2017 (Contd..6), H2 2017
    Products under Development by Companies, H2 2017 (Contd..7), H2 2017
    Products under Development by Companies, H2 2017 (Contd..8), H2 2017
    Products under Development by Companies, H2 2017 (Contd..9), H2 2017
    Products under Development by Companies, H2 2017 (Contd..10), H2 2017
    Products under Development by Companies, H2 2017 (Contd..11), H2 2017
    Products under Development by Companies, H2 2017 (Contd..12), H2 2017
    Products under Development by Companies, H2 2017 (Contd..13), H2 2017
    Products under Development by Companies, H2 2017 (Contd..14), H2 2017
    Products under Development by Companies, H2 2017 (Contd..15), H2 2017
    Products under Development by Companies, H2 2017 (Contd..16), H2 2017
    Products under Development by Companies, H2 2017 (Contd..17), H2 2017
    Products under Development by Companies, H2 2017 (Contd..18), H2 2017
    Products under Development by Companies, H2 2017 (Contd..19), H2 2017
    Products under Development by Companies, H2 2017 (Contd..20), H2 2017
    Products under Development by Universities/Institutes, H2 2017
    Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
    Number of Products by Stage and Target, H2 2017
    Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
    Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
    Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017
    Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017
    Number of Products by Stage and Target, H2 2017 (Contd..5), H2 2017
    Number of Products by Stage and Target, H2 2017 (Contd..6), H2 2017
    Number of Products by Stage and Target, H2 2017 (Contd..7), H2 2017
    Number of Products by Stage and Target, H2 2017 (Contd..8), H2 2017
    Number of Products by Stage and Mechanism of Action, H2 2017
    Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
    Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
    Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017
    Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017
    Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..5), H2 2017
    Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..6), H2 2017
    Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..7), H2 2017
    Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..8), H2 2017
    Number of Products by Stage and Route of Administration, H2 2017
    Number of Products by Stage and Molecule Type, H2 2017
    Kidney Cancer (Renal Cell Cancer)-Pipeline by 4SC AG, H2 2017
    Kidney Cancer (Renal Cell Cancer)-Pipeline by Aadi Bioscience Inc, H2 2017
    Kidney Cancer (Renal Cell Cancer)-Pipeline by AbbVie Inc, H2 2017
    Kidney Cancer (Renal Cell Cancer)-Pipeline by Actuate Therapeutics Inc, H2 2017
    Kidney Cancer (Renal Cell Cancer)-Pipeline by Adaptimmune Therapeutics Plc, H2 2017
    Kidney Cancer (Renal Cell Cancer)-Pipeline by Aduro BioTech Inc, H2 2017
    Kidney Cancer (Renal Cell Cancer)-Pipeline by Advanced Cancer Therapeutics LLC, H2 2017
    Kidney Cancer (Renal Cell Cancer)-Pipeline by Advenchen Laboratories LLC, H2 2017
    Kidney Cancer (Renal Cell Cancer)-Pipeline by Affitech A/S, H2 2017
    Kidney Cancer (Renal Cell Cancer)-Pipeline by Alethia Biotherapeutics Inc, H2 2017
    Kidney Cancer (Renal Cell Cancer)-Pipeline by Alkermes Plc, H2 2017
    Kidney Cancer (Renal Cell Cancer)-Pipeline by Altor BioScience Corp, H2 2017
    Kidney Cancer (Renal Cell Cancer)-Pipeline by Ambrx Inc, H2 2017
    Kidney Cancer (Renal Cell Cancer)-Pipeline by Amgen Inc, H2 2017
    Kidney Cancer (Renal Cell Cancer)-Pipeline by Ampio Pharmaceuticals Inc, H2 2017
    Kidney Cancer (Renal Cell Cancer)-Pipeline by Apac Biotech Pvt Ltd, H2 2017
    Kidney Cancer (Renal Cell Cancer)-Pipeline by Apcure SAS, H2 2017

    List of Figures
    Number of Products under Development for Kidney Cancer (Renal Cell Cancer), H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products under Development by Universities/Institutes, H2 2017
    Number of Products by Top 10 Targets, H2 2017
    Number of Products by Stage and Top 10 Targets, H2 2017
    Number of Products by Top 10 Mechanism of Actions, H2 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
    Number of Products by Routes of Administration, H2 2017
    Number of Products by Stage and Routes of Administration, H2 2017
    Number of Products by Top 10 Molecule Types, H2 2017
    Number of Products by Stage and Top 10 Molecule Types, H2 2017
    4SC AG
    Aadi Bioscience Inc
    AbbVie Inc
    Actuate Therapeutics Inc
    Adaptimmune Therapeutics Plc
    Aduro BioTech Inc
    Advanced Cancer Therapeutics LLC
    Advenchen Laboratories LLC
    Affitech A/S
    Alethia Biotherapeutics Inc
    Alkermes Plc
    Altor BioScience Corp
    Ambrx Inc
    Amgen Inc
    Ampio Pharmaceuticals Inc
    Apac Biotech Pvt Ltd
    Apcure SAS
    APEIRON Biologics AG
    Aphios Corp
    arGEN-X BV
    Argos Therapeutics Inc
    ARMO Biosciences Inc
    ArQule Inc
    Arrowhead Pharmaceuticals Inc
    Astellas Pharma Inc
    AstraZeneca Plc
    Bayer AG
    BeiGene Ltd
    Bio-Cancer Treatment International Ltd
    Biocad
    Biohaven Pharmaceutical Holding Company Ltd
    Bionomics Ltd
    Bionovis SA
    Biotest AG
    Boehringer Ingelheim GmbH
    Bristol-Myers Squibb Co
    Calithera Biosciences Inc
    CASI Pharmaceuticals Inc
    CBT Pharmaceuticals Inc
    Celgene Corp
    Celldex Therapeutics Inc
    Cellectar Biosciences Inc
    Cellular Biomedicine Group Inc
    Celyad SA
    Checkpoint Therapeutics Inc
    Chipscreen Biosciences Ltd
    Cleave Biosciences Inc
    Cleveland BioLabs Inc
    Clovis Oncology Inc
    COARE Biotechnology Inc
    Coherus BioSciences Inc
    Corvus Pharmaceuticals Inc
    Dr. Reddy's Laboratories Ltd
    Ecrins Therapeutics SAS
    Eisai Co Ltd
    Eli Lilly and Co
    Esperance Pharmaceuticals Inc
    Exelixis Inc
    F. Hoffmann-La Roche Ltd
    Gene Techno Science Co Ltd
    Genentech Inc
    Genor BioPharma Co Ltd
    GlaxoSmithKline Plc
    Glycotope GmbH
    Hemispherx Biopharma Inc
    HitGen LTD
    Horizon Pharma Plc
    Hutchison MediPharma Ltd
    Ignyta Inc
    Ildong Pharmaceutical Co Ltd
    Immune Design Corp
    Immune Pharmaceuticals Inc
    Immunicum AB
    ImmunoFrontier Inc
    ImmunoGen Inc
    Immunomedics Inc
    Immunomet Therapeutics Inc
    Incyte Corp
    Innovation Pharmaceuticals Inc
    Inovio Pharmaceuticals Inc
    Inspyr Therapeutics Inc
    Johnson & Johnson
    KAHR medical Ltd
    Karyopharm Therapeutics Inc
    KineMed Inc
    Kite Pharma Inc
    Konruns Pharmaceutical Co Ltd
    Kyowa Hakko Kirin Co Ltd
    Lead Discovery Center GmbH
    Lidds AB
    Lycera Corp
    MacroGenics Inc
    Madrigal Pharmaceuticals Inc.
    Mantis Therapeutics BV
    MaxiVAX SA
    MedImmune LLC
    Medinet Co Ltd
    Merck & Co Inc
    Merck KGaA
    Merrimack Pharmaceuticals Inc
    Mersana Therapeutics Inc
    Millennium Pharmaceuticals Inc
    Mirati Therapeutics Inc
    Moderna Therapeutics Inc
    Molecular Partners AG
    Moleculin Biotech Inc
    Mologen AG
    Monopar Therapeutics LLC
    Mycenax Biotech Inc
    NantKwest Inc
    NBE-Therapeutics AG
    Nektar Therapeutics
    NewLink Genetics Corp
    Novartis AG
    NovaTarg Therapeutics Inc
    Omeros Corp
    OncBioMune Pharmaceuticals Inc
    Oncobiologics Inc
    Oncolys BioPharma Inc
    OncoMax
    OncoTherapy Science Inc
    Oncovir Inc
    Ono Pharmaceutical Co Ltd
    Peloton Therapeutics Inc
    Pfizer Inc
    Pharma Mar SA
    Pharmicell Co Ltd
    Pivotal BioSciences Inc
    Plexxikon Inc
    PsiOxus Therapeutics Ltd
    Regeneron Pharmaceuticals Inc
    Rexahn Pharmaceuticals Inc
    Richter Gedeon Nyrt
    Sanofi
    Selvita SA
    Sevion Therapeutics Inc
    Shionogi & Co Ltd
    Sillajen Biotherapeutics
    Sorrento Therapeutics Inc
    Sumitomo Dainippon Pharma Co Ltd
    Sun Pharma Advanced Research Company Ltd
    Syndax Pharmaceuticals Inc
    Synthon Holdings BV
    Systimmune Inc
    Taiwan Liposome Company Ltd
    Taris Biomedical LLC
    TC BioPharm Ltd
    Tesaro Inc
    Tocagen Inc
    Tolero Pharmaceuticals Inc
    TRACON Pharmaceuticals Inc
    TVAX Biomedical Inc
    Tyrogenex Inc
    UroGen Pharmaceuticals Ltd
    Vaccibody AS
    Vascular Biogenics Ltd
    Vault Pharma Inc
    Vaxeal Holding SA
    ViiV Healthcare UK Ltd
    Vyriad Inc
    X4 Pharmaceuticals Inc
    Xspray Pharma AB

    Request for Sample

    Report Url https://www.reportsweb.com//kidney-cancer-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//kidney-cancer-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//kidney-cancer-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments